[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2187361A1 - Composition pharmaceutique contenant de la terazosine, pour le traitment du glaucome - Google Patents

Composition pharmaceutique contenant de la terazosine, pour le traitment du glaucome

Info

Publication number
CA2187361A1
CA2187361A1 CA002187361A CA2187361A CA2187361A1 CA 2187361 A1 CA2187361 A1 CA 2187361A1 CA 002187361 A CA002187361 A CA 002187361A CA 2187361 A CA2187361 A CA 2187361A CA 2187361 A1 CA2187361 A1 CA 2187361A1
Authority
CA
Canada
Prior art keywords
intraocular pressure
pharmaceutical composition
terazosin
pharmaceutically acceptable
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002187361A
Other languages
English (en)
Inventor
Takahiro Ogawa
Takaaki Deguchi
Katsuhiro Inada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2187361A1 publication Critical patent/CA2187361A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention se rapporte à une composition pharmaceutique de traitement du glaucome, qui comprend le composé (~)-4-amino-2-[4-(tétrahydro-2-furoyl)-1-pipérazinyl]-6,7-diméthoxyquinazoline ou un sel d'addition d'acide de ce composé acceptable sur le plan pharmaceutique, ainsi qu'un excipient acceptable sur le plan pharmaceutique.
CA002187361A 1994-05-18 1995-05-15 Composition pharmaceutique contenant de la terazosine, pour le traitment du glaucome Abandoned CA2187361A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6/103676 1994-05-18
JP10367694 1994-05-18

Publications (1)

Publication Number Publication Date
CA2187361A1 true CA2187361A1 (fr) 1995-11-23

Family

ID=14360400

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002187361A Abandoned CA2187361A1 (fr) 1994-05-18 1995-05-15 Composition pharmaceutique contenant de la terazosine, pour le traitment du glaucome

Country Status (10)

Country Link
EP (1) EP0759756A1 (fr)
JP (1) JPH10500130A (fr)
CN (1) CN1148810A (fr)
AU (1) AU2420195A (fr)
BR (1) BR9507732A (fr)
CA (1) CA2187361A1 (fr)
HU (1) HUT76468A (fr)
PL (1) PL317190A1 (fr)
TW (1) TW304879B (fr)
WO (1) WO1995031200A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004058A1 (fr) * 2001-07-02 2003-01-16 Santen Pharmaceutical Co., Ltd. Agents de protection du nerf optique contenant un bloqueur de recepteur $g(a)1 en tant qu'ingredient actif
US20040235932A1 (en) * 2001-07-13 2004-11-25 Kenji Yamazaki Ophthalmic pharmaceutical compositions
CN104840436B (zh) * 2015-06-11 2017-12-05 刘磊 药物组合物
JPWO2017002846A1 (ja) * 2015-06-30 2018-05-24 株式会社ニデック 視機能測定装置、および視機能測定プログラム
CN112439071B (zh) * 2019-09-04 2022-05-20 武汉科福新药有限责任公司 透皮促渗组合物及其在噻吗洛尔制剂中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
ES2038580T3 (es) * 1989-08-03 1994-10-16 Eisai Co Ltd Metodo de fotoestabilizacion de soluciones oftalmicas.
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones

Also Published As

Publication number Publication date
WO1995031200A1 (fr) 1995-11-23
HUT76468A (en) 1997-09-29
JPH10500130A (ja) 1998-01-06
BR9507732A (pt) 1997-08-19
EP0759756A1 (fr) 1997-03-05
AU2420195A (en) 1995-12-05
CN1148810A (zh) 1997-04-30
PL317190A1 (en) 1997-03-17
TW304879B (fr) 1997-05-11
HU9603158D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
US5663205A (en) Pharmaceutical composition for use in glaucoma treatment
EP2163548B1 (fr) Agent prophylactique ou thérapeutique pour la dégénérescence maculaire liée à l'âge
US20020045585A1 (en) Cytoskeletal active agents for glaucoma therapy
WO2003018057A1 (fr) Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3
EP0672417A1 (fr) Réduction de la pression intra-oculaire
CA2127519A1 (fr) Composition pharmaceutique utile en ophtalmologie
CA2187361A1 (fr) Composition pharmaceutique contenant de la terazosine, pour le traitment du glaucome
EP0968716B1 (fr) Medicaments pour le traitement des troubles circulatoires oculaires
AU677860B2 (en) Composition for prophylaxis and treatment of myopia
KR980008226A (ko) 시각기능장애의 예방 및 치료제
EP1225890B1 (fr) Utilisation de rivastigmine pour le traitement de troubles oculaires
US5308849A (en) Method of reducing elevated intraocular pressure
AU778148B2 (en) 2-aminotetralin derivatives for the therapy of glaucoma
EP0728480A1 (fr) Utilisation d'ifenprodil pour le traitement de la pression intraoculaire élevée
KR100585299B1 (ko) 시신경유두 순환 개선제
JPH04247036A (ja) 縮瞳をおこすことなく眼圧を下げる治療方法
EP0561913B1 (fr) Utilisation de derives de pyridine pour traiter l'hypertension oculaire
JP2741285B2 (ja) 緑内障治療剤
EP0456988B1 (fr) Utilisation du naproxen en tant qu'agent mydriatique
EP0607697A2 (fr) DILAZEP pour la réduction de la pression intraoculaire élevée
JPH04134029A (ja) 緑内障治療剤

Legal Events

Date Code Title Description
FZDE Dead